Holen Sie sich die Stockscreener-App
0.2327
1.90%
-0.0045
Handel nachbörslich:
.24
0.0073
+3.14%
Schlusskurs vom Vortag:
$0.2372
Offen:
$0.23
24-Stunden-Volumen:
5.63M
Relative Volume:
0.51
Marktkapitalisierung:
$3.39M
Einnahmen:
$88,000
Nettoeinkommen (Verlust:
$-13.96M
KGV:
-0.035
EPS:
-6.6545
Netto-Cashflow:
$-11.34M
1W Leistung:
-43.38%
1M Leistung:
-55.01%
6M Leistung:
-84.57%
1J Leistung:
+145.45%
1-Tages-Spanne:
$0.2275
$0.2393
1-Wochen-Bereich:
$0.21
$0.459
52-Wochen-Spanne:
$0.21
$20.33
AIM ImmunoTech Inc Stock (AIM) Company Profile
Firmenname
AIM ImmunoTech Inc
Sektor
Branche
Telefon
352 448 7797
Adresse
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.2327 | 3.45M | 88,000 | -13.96M | -11.34M | -6.6545 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
AIM ImmunoTech Inc Aktie (AIM) Neueste Nachrichten
AIM Should I Buy - Intellectia AI
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
AIM ImmunoTech Announces Equity Offering to Bolster Capital - TipRanks
AIM ImmunoTech (NYSE: AIM) offers 7.52M shares; private warrants for 15.04M - Stock Titan
AIM ImmunoTech Raises $2.4M in Registered Direct, Adds $4.9M Warrant Upside at $0.325 - TradingView
AIM ImmunoTech (NYSE: AIM) raises $2.4M via stock sale and warrants - Stock Titan
AIM ImmunoTech prices $2.4M registered direct offering By Investing.com - Investing.com South Africa
AIM ImmunoTech prices $2.4M registered direct offering - Investing.com UK
AIM ImmunoTech announces $2.4M registered direct offering - TipRanks
AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct ... - Caledonian Record
Press Release: AIM ImmunoTech Announces $2.4 Million Financing, Including Concurrent Registered Direct Offering and Private Placement - 富途牛牛
Maxim Group Maintains AIM ImmunoTech(AIM.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
AIM Stock Price, Quote & Chart | AIM IMMUNOTECH INC (NYSEARCA:AIM) - ChartMill
AIM ImmunoTech Inc. has officially suspended its equity distribution agreement and will terminate its continuous offering program effective from May 19, 2026. - Bitget
AIM Immunotech (NYSE American: AIM) suspends ATM program after $2.85M sold - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
AIM ImmunoTech Boosts Stockholder Equity by $11.9 Million and Extends Promissory Note to 2027 to Advance Pancreatic Cancer Strategy 12 - Minichart
AIM ImmunoTech extends debt maturity, reports equity gain By Investing.com - Investing.com South Africa
AIM ImmunoTech announces significant increase in stockholder equity and extension of promissory note maturity date to June 2027 - marketscreener.com
Aim Immunotech Announces Significant Increase In Stockholder Equity And Extension Of Promissory Note Maturity Date To June 2027 - TradingView
AIM ImmunoTech Strengthens Equity Position and Financial Flexibility - TipRanks
AIM ImmunoTech Inc. announced an extension to the maturity date of one of its promissory notes. - Bitget
AIM ImmunoTech extends debt maturity, reports equity gain - Investing.com
AIM ImmunoTech Extends Streeterville Promissory Note to 2027; Adds $10,000 Fee, $1.68M Balance - TradingView
AIM ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing Financial Flexibility and Supporting Strategic Clinical Priorities - The Manila Times
AIM ImmunoTech equity jumps $11.9M, debt pushed to 2027 for pancreatic cancer - Stock Titan
Equity swings positive as AIM ImmunoTech (NYSE: AIM) extends note to 2027 - Stock Titan
AIM ImmunoTech Inc. Amends Promissory Note Agreement With Streeterville Capital and Extends Maturity Date to June 30, 2027 - marketscreener.com
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
12 Health Care Stocks Moving In Monday's Pre-Market Session - Sahm
12 Health Care Stocks Moving In Monday's After-Market SessionAIM ImmunoTech (AMEX:AIM), Atlantic Inter - Benzinga
$AIM ImmunoTech (AIM.US)$ buy sell flyy🔥 - Moomoo
AIM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
AIM ImmunoTech (AIM) posts Q1 2026 loss, flags going concern and NYSE equity shortfall - Stock Titan
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer - Sahm
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader Segment - The National Law Review
AIM ImmunoTech Posts Virtual Investor Key Opinion Leader - GlobeNewswire
AIM ImmunoTech Highlights Ampligen’s Positive Phase 2 Data in Late-Stage Pancreatic Cancer and Survival Benefits - Minichart
AIM ImmunoTech Highlights Ampligen Progress in Pancreatic Cancer - TipRanks
AIM ImmunoTech Reports Positive Data from Named Patient Program and Interim Results from Phase 2 Study of Ampligen® for Late-Stage Pancreatic Cancer - Quiver Quantitative
AIM ImmunoTech (NYSE: AIM) showcases Ampligen pancreatic cancer data in KOL segment - Stock Titan
Pancreatic cancer data show 22.3‑month survival gain with Ampligen - Stock Titan
Earnings Scheduled For May 13, 2026 - Benzinga
AIM ImmunoTech Company Profile & Introduction - Moomoo
AIM ImmunoTech raises $3.6 million through warrant inducement transaction By Investing.com - Investing.com Nigeria
AIM ImmunoTech raises $3.6 million through warrant inducement transaction - Investing.com
AIM ImmunoTech Raises Capital Through Warrant Exercise Inducement - TipRanks
Orca Capital reports 1.79M shares in AIM ImmunoTech (NASDAQ: AIM) - Stock Titan
AIM ImmunoTech (NYSE: AIM) gets $3.6M from warrant exercise inducement deal - Stock Titan
MSN Money - MSN
Finanzdaten der AIM ImmunoTech Inc-Aktie (AIM)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):